Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.
| dc.contributor.author | Lee, S | |
| dc.contributor.author | Lewanski, C | |
| dc.contributor.author | Counsell, N | |
| dc.contributor.author | Ottensmeier, C | |
| dc.contributor.author | Bates, A | |
| dc.contributor.author | Patel, N | |
| dc.contributor.author | Wadsworth, C | |
| dc.contributor.author | Ngai, Y | |
| dc.contributor.author | Hackshaw, A | |
| dc.contributor.author | Faivre-Finn, Corinne | |
| dc.date.accessioned | 2014-09-04T09:12:49Z | |
| dc.date.available | 2014-09-04T09:12:49Z | |
| dc.date.issued | 2014-07 | |
| dc.identifier.citation | Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases. 2014, 106 (7): J Natl Cancer Inst | en |
| dc.identifier.issn | 1460-2105 | |
| dc.identifier.pmid | 25031274 | |
| dc.identifier.doi | 10.1093/jnci/dju151 | |
| dc.identifier.uri | http://hdl.handle.net/10541/325852 | |
| dc.description.abstract | Median survival of non-small cell lung cancer (NSCLC) patients with brain metastases is poor. We examined concurrent erlotinib and whole brain radiotherapy (WBRT) followed by maintenance erlotinib in patients with untreated brain metastases, given the potential radiosensitizing properties of erlotinib and its direct effect on brain metastases and systemic activity. | |
| dc.language.iso | en | en |
| dc.rights | Archived with thanks to Journal of the National Cancer Institute | en |
| dc.title | Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases. | en |
| dc.type | Article | en |
| dc.contributor.department | Department of Oncology, University College London (UCL) Cancer Institute and UCL Hospitals, London, UK | en |
| dc.identifier.journal | Journal of the National Cancer Institute | en |
| html.description.abstract | Median survival of non-small cell lung cancer (NSCLC) patients with brain metastases is poor. We examined concurrent erlotinib and whole brain radiotherapy (WBRT) followed by maintenance erlotinib in patients with untreated brain metastases, given the potential radiosensitizing properties of erlotinib and its direct effect on brain metastases and systemic activity. |